代謝異常治療の市場規模、シェア、動向分析レポート：疾患別、治療法別、投与経路別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

代謝異常治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の代謝性疾患治療市場規模は、2025～2030年にかけて7.8%のCAGRを記録し、2030年までに1,207億1,000万米ドルに達する見込みです。

糖尿病、肥満、高コレステロール血症の増加が市場成長の原動力になると予測されています。2040年までに、世界の約11人に1人が前述の疾患のいずれかに罹患すると推定されています。

調査担当者は、肥満や糖尿病などの代謝性疾患の有病率は、米国やアジア・中南米諸国を中心に、今後20年間で倍増すると予測しています。このことは、今後の市場全体の成長を後押しすると考えられます。さらに、新興諸国の経済が安定するにつれて、1回限りの治療を目的とした新規治療に対する需要が高まっています。このため、世界市場の大手企業は、革新的な治療法を開発するために研究開発に多額の投資を行っています。これらすべての要因が市場開拓に寄与するものと考えられます。

代謝異常治療市場レポートハイライト

• 糖尿病が市場を独占し、2024年には29.8%のシェアを占めました。これは、糖尿病、特に2型糖尿病の有病率が増加し、世界人口の5%以上が罹患していることが背景にあります。
• ライソゾーム貯蔵病（LSDs）は、予測期間中最も速いCAGR 9.3％で成長すると予想されます。LSDは酵素欠乏に起因する進行性の神経疾患であり、重篤な症状と早期死亡を引き起こします。
• 酵素補充療法（ERT）は2024年の売上高シェア30.6％で市場をリードしています。ERTは、ライソゾーム貯蔵障害に関連する基本的な酵素欠損を標的とし、患者の健康とQOLを大幅に改善します。
• 遺伝子治療は、予測期間中に9.7%という最速の伸びを示すと予想されています。遺伝子治療は、治療の選択肢が限られている遺伝性代謝性疾患の治療ソリューションを提供する大きな可能性を秘めています。
• 非経口治療は、迅速な作用発現と高い生物学的利用能に助けられ、2024年には50.0％の最大市場シェアを占めました。非経口投与は消化管を効果的にバイパスするため、初回通過代謝が回避され、即効的な治療効果が期待できます。
• 経口治療は、予測期間中に最も速いCAGR 8.2％を記録すると予想されます。経口投与は非侵襲的で、患者が自己投与しやすく、一般的に注射よりも好まれるため、治療アドヒアランスが向上
• 2024年の売上シェアは44.6%で、病院薬局が市場を独占しています。病院薬局は、特に専門的な取り扱いが必要な代謝性疾患など、複雑な薬剤の調剤において重要な役割を果たしています。
• 北米の代謝異常治療市場は、2024年の売上高シェア39.9%で世界市場を独占しました。北米は、強力な医療インフラ、研究開発への多額の投資、糖尿病や肥満などの代謝性疾患の顕著な有病率を誇っています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 代謝障害治療市場の変数、動向、範囲

• 市場系統の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析

第4章 代謝障害治療市場：疾患ビジネス分析

• 疾病市場シェア、2024年と2030年
• 疾患セグメントダッシュボード
• 市場規模と予測と動向分析、疾患別、2018～2030年
• リソソーム蓄積疾患
• 糖尿病
• 肥満
• 遺伝性代謝疾患
• 高コレステロール血症
• その他の代謝疾患

第5章 代謝障害治療市場：治療法ビジネス分析

• 治療法市場シェア、2024年と2030年
• 治療法セグメントダッシュボード
• 市場規模と予測と動向分析、治療法別、2018～2030年
• 酵素補充療法
• 細胞移植
• 低分子ベースの治療法
• 基質還元療法
• 遺伝子治療
• 薬剤療法

第6章 代謝障害治療市場：投与経路ビジネス分析

• 投与経路市場シェア、2024年と2030年
• 投与経路セグメントダッシュボード
• 市場規模と予測と動向分析、投与経路別、2018～2030年
• 経口
• 非経口
• その他

第7章 代謝障害治療市場：流通チャネルビジネス分析

• 流通チャネル市場シェア、2024年と2030年
• 流通チャネルセグメントダッシュボード
• 市場規模と予測と動向分析、流通チャネル別、2018～2030年
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 代謝障害治療市場：疾患、治療法、投与経路、流通チャネルによる地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 国別、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 国別、2018～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • デンマーク
  • スウェーデン
• アジア太平洋
  • 国別、2018～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • 国別、2018～2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 国別、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Merck KGaA
  • AstraZeneca
  • AbbVie Inc.
  • Johnson & Johnson Innovative Medicine
  • Amgen Inc.
  • Biocon
  • BioMarin
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global metabolic disorder therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 4. Global metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 5. Global metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 6. Global metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 7. Global metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 8. North America metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
• Table 9. North America metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 10. North America metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 11. North America metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 12. North America metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 13. U.S. metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 14. U.S. metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 15. U.S. metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 16. U.S. metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 17. Canada metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 18. Canada metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 19. Canada metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 20. Canada metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 21. Mexico metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 22. Mexico metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 23. Mexico metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 24. Mexico metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 25. Europe metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
• Table 26. Europe metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 27. Europe metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 28. Europe metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 29. Europe metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 30. UK metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 31. UK metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 32. UK metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 33. UK metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 34. Germany metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 35. Germany metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 36. Germany metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 37. Germany metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 38. France metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 39. France metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 40. France metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 41. France metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 42. Italy metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 43. Italy metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 44. Italy metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 45. Italy metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 46. Spain metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 47. Spain metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 48. Spain metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 49. Spain metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 50. Denmark metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 51. Denmark metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 52. Denmark metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 53. Denmark metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 54. Sweden metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 55. Sweden metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 56. Sweden metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 57. Sweden metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 58. Norway metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 59. Norway metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 60. Norway metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 61. Norway metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 62. Asia Pacific metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
• Table 63. Asia Pacific metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 64. Asia Pacific metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 65. Asia Pacific metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 66. Asia Pacific metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 67. China metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 68. China metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 69. China metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 70. China metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 71. Japan metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 72. Japan metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 73. Japan metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 74. Japan metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 75. India metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 76. India metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 77. India metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 78. India metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 79. Australia metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 80. Australia metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 81. Australia metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 82. Australia metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 83. South Korea metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 84. South Korea metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 85. South Korea metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 86. South Korea metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87. Thailand metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 88. Thailand metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 89. Thailand metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 90. Thailand metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 91. Latin America metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
• Table 92. Latin America metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 93. Latin America metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 94. Latin America metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 95. Latin America metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 96. Brazil metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 97. Brazil metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 98. Brazil metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 99. Brazil metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 100. Argentina metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 101. Argentina metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 102. Argentina metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 103. Argentina metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 104. Middle East & Africa Metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
• Table 105. Middle East & Africa metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 106. Middle East & Africa metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 107. Middle East & Africa metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 108. Middle East & Africa metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 109. South Africa metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 110. South Africa metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 111. South Africa metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 112. South Africa metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 113. Saudi Arabia metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 114. Saudi Arabia metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 115. Saudi Arabia metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 116. Saudi Arabia metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 117. UAE metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 118. UAE metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 119. UAE metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 120. UAE metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 121. Kuwait metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
• Table 122. Kuwait metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
• Table 123. Kuwait metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 124. Kuwait metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Metabolic disorder therapeutics market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Disease and therapy outlook (USD Million)
• Fig. 10 Route of administration and distribution channel outlook (USD Million)
• Fig. 11 Competitive landscape
• Fig. 12 Metabolic disorder therapeutics market dynamics
• Fig. 13 Metabolic disorder therapeutics market: Porter's five forces analysis
• Fig. 14 Metabolic disorder therapeutics market: PESTLE analysis
• Fig. 15 Metabolic disorder therapeutics market: Disease segment dashboard
• Fig. 16 Metabolic disorder therapeutics market: Disease market share analysis, 2024 & 2030
• Fig. 17 Lysosomal storage diseases market, 2018 - 2030 (USD Million)
• Fig. 18 Diabetes market, 2018 - 2030 (USD Million)
• Fig. 19 Obesity market, 2018 - 2030 (USD Million)
• Fig. 20 Inherited metabolic disorders market, 2018 - 2030 (USD Million)
• Fig. 21 Hypercholesterolemia market, 2018 - 2030 (USD Million)
• Fig. 22 Other metabolic diseases market, 2018 - 2030 (USD Million)
• Fig. 23 Metabolic disorder therapeutics market: Therapy segment dashboard
• Fig. 24 Metabolic disorder therapeutics market: Therapy market share analysis, 2024 & 2030
• Fig. 25 Enzyme replacement therapy market, 2018 - 2030 (USD Million)
• Fig. 26 Cellular transplantation market, 2018 - 2030 (USD Million)
• Fig. 27 Small molecule based therapy market, 2018 - 2030 (USD Million)
• Fig. 28 Substrate reduction therapy market, 2018 - 2030 (USD Million)
• Fig. 29 Gene therapy market, 2018 - 2030 (USD Million)
• Fig. 30 Drug therapy market, 2018 - 2030 (USD Million)
• Fig. 31 Metabolic disorder therapeutics market: Route of administration segment dashboard
• Fig. 32 Metabolic disorder therapeutics market: Route of administration market share analysis, 2024 & 2030
• Fig. 33 Oral market, 2018 - 2030 (USD Million)
• Fig. 34 Parenteral market, 2018 - 2030 (USD Million)
• Fig. 35 Others market, 2018 - 2030 (USD Million)
• Fig. 36 Metabolic disorder therapeutics market: Distribution channel segment dashboard
• Fig. 37 Metabolic disorder therapeutics market: Distribution channel market share analysis, 2024 & 2030
• Fig. 38 Hospital pharmacies market, 2018 - 2030 (USD Million)
• Fig. 39 Retail pharmacies market, 2018 - 2030 (USD Million)
• Fig. 40 Online pharmacies market, 2018 - 2030 (USD Million)
• Fig. 41 Metabolic disorder therapeutics market revenue, by region
• Fig. 42 Regional marketplace: Key takeaways
• Fig. 43 Regional marketplace: Key takeaways
• Fig. 44 North America metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 45 U.S. country dynamics
• Fig. 46 U.S. metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 47 Canada country dynamics
• Fig. 48 Canada metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 49 Mexico country dynamics
• Fig. 50 Mexico metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 51 Europe metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 52 UK country dynamics
• Fig. 53 UK metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 54 Germany country dynamics
• Fig. 55 Germany metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 56 France country dynamics
• Fig. 57 France metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 58 Italy country dynamics
• Fig. 59 Italy metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 60 Spain country dynamics
• Fig. 61 Spain metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 62 Norway country dynamics
• Fig. 63 Norway metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 64 Sweden country dynamics
• Fig. 65 Sweden metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 66 Denmark country dynamics
• Fig. 67 Denmark metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 68 Asia Pacific metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 69 Japan country dynamics
• Fig. 70 Japan metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 71 China country dynamics
• Fig. 72 China metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 73 India country dynamics
• Fig. 74 India metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 75 Australia country dynamics
• Fig. 76 Australia metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 77 South Korea country dynamics
• Fig. 78 South Korea metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 79 Thailand country dynamics
• Fig. 80 Thailand metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 81 Latin America metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 82 Brazil country dynamics
• Fig. 83 Brazil metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 84 Argentina country dynamics
• Fig. 85 Argentina metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 86 MEA metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 87 South Africa country dynamics
• Fig. 88 South Africa metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 89 Saudi Arabia country dynamics
• Fig. 90 Saudi Arabia metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 91 UAE country dynamics
• Fig. 92 UAE metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 93 Kuwait country dynamics
• Fig. 94 Kuwait metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
• Fig. 95 Company categorization
• Fig. 96 Company market position analysis
• Fig. 97 Strategic framework

Metabolic Disorder Therapeutics Market Growth & Trends:

The global metabolic disorder therapeutics market size is expected to reach USD 120.71 billion by 2030, registering a CAGR of 7.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising incidences of diabetes, obesity, and hypercholesterolemia are expected to drive the market growth. It is estimated that by 2040, about 1 person in 11 people worldwide is likely to suffer from one of the aforementioned diseases.

Researchers estimate that the prevalence of metabolic diseases like obesity and diabetes is expected to double in the coming 2 decades, mainly in U.S. and Asian and Latin American countries. This, in turn, will help boost the overall market growth in the year to come. Furthermore, with better economic stability in developing countries, demand for novel therapeutics for one-time treatment has increased. This has made major companies in the global market to invest heavily in R&D to develop innovative therapy options. All these factors will contribute to the development of the market.

Metabolic Disorder Therapeutics Market Report Highlights:

• Diabetes dominated the market and accounted for a share of 29.8% in 2024, driven by the increasing prevalence of diabetes, particularly type 2 diabetes, affecting more than 5% of the global population.
• Lysosomal storage diseases (LSDs) are expected to grow at the fastest CAGR of 9.3% over the forecast period. LSDs are progressive neurological conditions resulting from enzyme deficiencies, causing severe symptoms and early mortality.
• Enzyme replacement therapy (ERT) led the market with a revenue share of 30.6% in 2024. ERT targets the fundamental enzyme deficiencies associated with lysosomal storage disorders, significantly improving patient health and quality of life.
• Gene therapy is anticipated to witness the fastest rate of 9.7% over the forecast period. Gene therapy holds significant potential to offer curative solutions for inherited metabolic diseases with limited treatment options.
• Parenteral therapeutics held the largest market share of 50.0% in 2024, aided by rapid onset of action and high bioavailability. Parenteral administration effectively bypasses the gastrointestinal tract, avoiding first-pass metabolism, crucial for immediate therapeutic effects.
• Oral therapeutics are expected to register the fastest CAGR of 8.2% over the forecast period. Oral administration is non-invasive, easy for patients to self-administer, and typically preferred over injections, resulting in higher treatment adherence.
• Hospital pharmacies dominated the market with a revenue share of 44.6% in 2024. Hospital pharmacies play a vital role in dispensing complex medications, particularly for metabolic disorders that necessitate specialized handling.
• North America metabolic disorder therapeutics market dominated the global market with a revenue share of 39.9% in 2024. North America boasts a strong healthcare infrastructure, substantial investments in research and development, and a notable prevalence of metabolic disorders such as diabetes and obesity.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease
  • 1.2.2. Therapy
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Metabolic Disorder Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Metabolic Disorder Therapeutics Market: Disease Business Analysis

• 4.1. Disease Market Share, 2024 & 2030
• 4.2. Disease Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
• 4.4. Lysosomal Storage Diseases
  • 4.4.1. Lysosomal Storage Diseases Market, 2018 - 2030 (USD Million)
• 4.5. Diabetes
  • 4.5.1. Diabetes Market, 2018 - 2030 (USD Million)
• 4.6. Obesity
  • 4.6.1. Obesity Market, 2018 - 2030 (USD Million)
• 4.7. Inherited Metabolic Disorders
  • 4.7.1. Inherited Metabolic Disorders Market, 2018 - 2030 (USD Million)
• 4.8. Hypercholesterolemia
  • 4.8.1. Hypercholesterolemia Market, 2018 - 2030 (USD Million)
• 4.9. Other Metabolic Diseases
  • 4.9.1. Other Metabolic Diseases Market, 2018 - 2030 (USD Million)

Chapter 5. Metabolic Disorder Therapeutics Market: Therapy Business Analysis

• 5.1. Therapy Market Share, 2024 & 2030
• 5.2. Therapy Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
• 5.4. Enzyme Replacement Therapy
  • 5.4.1. Enzyme Replacement Therapy Market, 2018 - 2030 (USD Million)
• 5.5. Cellular Transplantation
  • 5.5.1. Cellular Transplantation Market, 2018 - 2030 (USD Million)
• 5.6. Small Molecule Based Therapy
  • 5.6.1. Small Molecule Based Therapy Market, 2018 - 2030 (USD Million)
• 5.7. Substrate Reduction Therapy
  • 5.7.1. Substrate Reduction Therapy Market, 2018 - 2030 (USD Million)
• 5.8. Gene Therapy
  • 5.8.1. Gene Therapy Market, 2018 - 2030 (USD Million)
• 5.9. Drug Therapy
  • 5.9.1. Drug Therapy Market, 2018 - 2030 (USD Million)

Chapter 6. Metabolic Disorder Therapeutics Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2024 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
• 6.5. Parenteral
  • 6.5.1. Parenteral Market, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Metabolic Disorder Therapeutics Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2024 & 2030
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Metabolic Disorder Therapeutics Market: Regional Estimates & Trend Analysis by Disease, Therapy, Route of Administration, and Distribution Channel

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory Framework
    • 8.4.2.3. Competitive Insights
    • 8.4.2.4. U.S. Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory Framework
    • 8.4.3.3. Competitive Insights
    • 8.4.3.4. Canada Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Regulatory Framework
    • 8.4.4.3. Competitive Insights
    • 8.4.4.4. Mexico Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory Framework
    • 8.5.2.3. Competitive Insights
    • 8.5.2.4. UK Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory Framework
    • 8.5.3.3. Competitive Insights
    • 8.5.3.4. Germany Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Regulatory Framework
    • 8.5.4.3. Competitive Insights
    • 8.5.4.4. France Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Regulatory Framework
    • 8.5.5.3. Competitive Insights
    • 8.5.5.4. Italy Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Regulatory Framework
    • 8.5.6.3. Competitive Insights
    • 8.5.6.4. Spain Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Regulatory Framework
    • 8.5.7.3. Competitive Insights
    • 8.5.7.4. Norway Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Regulatory Framework
    • 8.5.8.3. Competitive Insights
    • 8.5.8.4. Denmark Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Sweden
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Regulatory Framework
    • 8.5.9.3. Competitive Insights
    • 8.5.9.4. Sweden Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory Framework
    • 8.6.2.3. Competitive Insights
    • 8.6.2.4. Japan Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory Framework
    • 8.6.3.3. Competitive Insights
    • 8.6.3.4. China Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory Framework
    • 8.6.4.3. Competitive Insights
    • 8.6.4.4. India Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory Framework
    • 8.6.5.3. Competitive Insights
    • 8.6.5.4. South Korea Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Regulatory Framework
    • 8.6.6.3. Competitive Insights
    • 8.6.6.4. Australia Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Regulatory Framework
    • 8.6.7.3. Competitive Insights
    • 8.6.7.4. Thailand Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Regulatory Framework
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. Brazil Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Regulatory Framework
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. Argentina Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Regulatory Framework
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. South Africa Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Regulatory Framework
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. Saudi Arabia Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Regulatory Framework
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. UAE Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Regulatory Framework
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. Kuwait Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Novo Nordisk A/S
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Eli Lilly and Company
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Takeda Pharmaceutical Company Limited
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Sanofi
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Merck KGaA
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. AstraZeneca
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. AbbVie Inc.
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Johnson & Johnson Innovative Medicine
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Amgen Inc.
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Biocon
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. BioMarin
    • 9.5.11.1. Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Product Benchmarking
    • 9.5.11.4. Strategic Initiatives
  • 9.5.12. Boehringer Ingelheim International GmbH
    • 9.5.12.1. Overview
    • 9.5.12.2. Financial Performance
    • 9.5.12.3. Product Benchmarking
    • 9.5.12.4. Strategic Initiatives
  • 9.5.13. Bristol-Myers Squibb Company
    • 9.5.13.1. Overview
    • 9.5.13.2. Financial Performance
    • 9.5.13.3. Product Benchmarking
    • 9.5.13.4. Strategic Initiatives
  • 9.5.14. Cipla Inc.
    • 9.5.14.1. Overview
    • 9.5.14.2. Financial Performance
    • 9.5.14.3. Product Benchmarking
    • 9.5.14.4. Strategic Initiatives